Syntekabio Introduces Develop Now, Pay Later with AI-powered STB LaunchPad Program Company invests in the success of its clients in bringing novel treatments to patients
DAEJEON, Rep. of Korea and New York, NY USA
|
August 29, 2024 10:15 AM Eastern Daylight Time
![](https://public.newsdirect.com/910598144/mo9V2D7a.png)
Syntekabio (KOSDAQ: 226330), an artificial intelligence (AI) based drug development company, today announced its innovative new offer designed to minimize risk, save time and costs, and increase the success rate of companies developing novel therapies.
The new ‘Develop Now, Pay Later’ offer is Syntekabio’s latest initiative to invest in the success of its clients. This model enables pharmaceutical and biotechnology companies to test the validity of a target protein of interest without incurring any upfront costs. Should a project demonstrate viability, Syntekabio then employs its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher® technology platform, to deliver hits and optimized leads as well as IND-enabled candidates.
Jongsun Jung, PhD, CEO of Syntekabio, remarked, “We want our clients to achieve their goal of bringing safer and more effective therapies to patients. Thus, our mission at Syntekabio is to deliver to our clients first-in-class or best-in-class compounds, fast. We strongly believe in the capability of our technology and so, to further invest in our clients’ success, we have introduced our Develop Now, Pay Later model to support groundbreaking drug development work and reduce the risk for our clients at the outset.”
Syntekabio is dedicated to making drug discovery as optimized and as low risk as possible. Clients can first take advantage of a complimentary feasibility study to determine if their project is viable. The next step is to submit any target protein for analysis via the STB LaunchPad program. There are no upfront fees. The client only pays for the work once the agreed upon validated results are obtained.
Syntekabio’s AI accesses over 10 billion known compounds as well as 1,400 in vitro/in vivo compatible drug targets covering over 70% of human diseases. This technology is powered by Syntekabio’s AI Bio-Supercom Center, which houses an immense infrastructure of 5,000 servers, 40,000 CPU cores, and 2,500 GPUs fueling the Company’s algorithms. The Company has a comprehensive suite of advanced proprietary tools designed to accelerate the drug discovery and development process.
For more information about Syntekabio, STB LaunchPad and Develop Now, Pay Later, please click here.
About Syntekabio
Syntekabio Co., Ltd. (KOSDAQ: 226330) is a drug discovery company bringing together biology and AI/ML since 2009 and facilitating the discovery of first-in-class and best-in-class compounds, rapidly. The Company has its own supercomputer cloud, along with a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a one-stop shop, with technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. Syntekabio’s disease-agnostic physics-based platform generates a continual stream of hits, leads, and drug candidates that are readily available for purchase. The Company also undertakes client-specific projects to identify highly promising development candidates for specific targets and indications. Visit the Syntekabio website at www.syntekabio.com or follow the Company on LinkedIn for the latest updates.
Contact Details
MC Services AG - Media inquiries (US)
Laurie Doyle
+1 339-832-0752
Company Website